MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$390K
Net Income
-$8,979K
Net Profit Margin
-2302.31%
EPS
-$0.2
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-09-30
2025-06-30
Product revenue, net
390
-
Cost of sales
20
345
Amortization of intangible asset
349
-
Research and development
1,261
1,000
General and administrative
-
4,184
Selling, general and administrative
6,491
-
Total operating expenses
8,121
5,529
Operating loss
-7,731
-5,529
Interest expense, net
-441
-316
Adjustments to fair value of derivatives
-673
-585
Other expense, net
-2
-20
Total other expense
-1,116
-921
Loss before income taxes
-8,847
-6,450
Income tax expense
132
59
Net loss
-8,979
-6,509
Basic EPS
-0.2
-0.16
Diluted EPS
-0.2
-0.16
Basic Average Shares
45,801,927
39,935,213
Diluted Average Shares
45,801,927
39,935,213
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$8,979K
Loss before income
taxes
-$8,847K
Income tax expense
$132K
Operating loss
-$7,731K
Total other expense
-$1,116K
Product revenue, net
$390K
Total operating
expenses
$8,121K
Adjustments to fair value of
derivatives
-$673K
Interest expense, net
-$441K
Other expense, net
-$2K
Selling, general and
administrative
$6,491K
Research and development
$1,261K
Amortization of intangible
asset
$349K
Cost of sales
$20K
Buy us a coffee
Iterum Therapeutics plc (ITRM)
Iterum Therapeutics plc (ITRM)